Qiagen Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Qiagen wird ein jährliches Gewinn- und Umsatzwachstum von 34.4% bzw. 7.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 35.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12% betragen.

Wichtige Informationen

34.4%

Wachstumsrate der Gewinne

35.5%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	18.4%
Wachstumsrate der Einnahmen	7.4%
Zukünftige Eigenkapitalrendite	12.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03

Recent updates

Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

Oct 11

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Sep 24

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

May 21

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Gewinn- und Umsatzwachstumsprognosen

NYSE:QGEN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,236	507	537	704	16
12/31/2025	2,090	422	464	644	19
12/31/2024	1,980	166	296	614	19
9/30/2024	1,966	93	460	633	N/A
6/30/2024	1,940	73	405	576	N/A
3/31/2024	1,939	337	358	521	N/A
12/31/2023	1,965	341	297	459	N/A
9/30/2023	1,954	332	275	432	N/A
6/30/2023	1,978	337	376	519	N/A
3/31/2023	1,999	353	430	580	N/A
12/31/2022	2,142	423	566	715	N/A
9/30/2022	2,226	488	660	826	N/A
6/30/2022	2,261	539	580	770	N/A
3/31/2022	2,313	563	556	755	N/A
12/31/2021	2,252	513	432	639	N/A
9/30/2021	2,240	311	516	745	N/A
6/30/2021	2,190	480	337	592	N/A
3/31/2021	2,065	449	239	571	N/A
12/31/2020	1,870	359	154	458	N/A
9/30/2020	1,713	191	10	298	N/A
6/30/2020	1,612	14	108	333	N/A
3/31/2020	1,550	-31	152	302	N/A
12/31/2019	1,526	-41	56	331	N/A
9/30/2019	1,516	-25	60	332	N/A
6/30/2019	1,511	196	58	342	N/A
3/31/2019	1,507	188	87	356	N/A
12/31/2018	1,502	190	209	359	N/A
9/30/2018	1,496	90	189	325	N/A
6/30/2018	1,482	78	N/A	324	N/A
3/31/2018	1,453	55	N/A	275	N/A
12/31/2017	1,418	40	N/A	287	N/A
9/30/2017	1,387	89	N/A	311	N/A
6/30/2017	1,362	75	N/A	323	N/A
3/31/2017	1,347	82	N/A	353	N/A
12/31/2016	1,338	80	N/A	342	N/A
9/30/2016	1,320	123	N/A	328	N/A
6/30/2016	1,296	123	N/A	331	N/A
3/31/2016	1,281	126	N/A	303	N/A
12/31/2015	1,281	130	N/A	317	N/A
9/30/2015	1,293	104	N/A	310	N/A
6/30/2015	1,315	105	N/A	303	N/A
3/31/2015	1,326	113	N/A	305	N/A
12/31/2014	1,345	116	N/A	288	N/A
9/30/2014	1,345	151	N/A	291	N/A
6/30/2014	1,331	157	N/A	284	N/A
3/31/2014	1,315	72	N/A	259	N/A
12/31/2013	1,302	69	N/A	259	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: QGENDas prognostizierte Gewinnwachstum (34.4% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: QGENDie Erträge des Unternehmens (34.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: QGENEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: QGENDie Einnahmen des Unternehmens (7.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: QGENDie Einnahmen des Unternehmens (7.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: QGENDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12%).

Qiagen Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 13%

Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024

Qiagen N.V. Updates Earnings Guidance for the Full Year 2024

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024

Qiagen N.V. Provides Earnings Guidance for Year 2024

Recent updates

Consensus EPS estimates fall by 13%

Qiagen Collaborates with McGill University to Advance Microbiome Research

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024

QIAGEN Receives FDA Clearance of QIAstat-Dx Meningitis/Encephalitis Panel to Support Emergency Diagnostics

QIAGEN Receives FDA Clearance for QIAstat-Dx Mini Panel to Improve Precision in Outpatient Respiratory Treatment

Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

QIAGEN Expands Automated Liquid Biopsy Portfolio to Enhance Oncology, Prenatal Care and Organ Transplant Applications

Qiagen N.V. to Report Q3, 2024 Results on Nov 06, 2024

QIAGEN N.V. Launches QIAcuityDx Digital PCR System for Clinical Testing in Oncology

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

CFO, MD & Member of Management Board recently sold US$745k worth of stock

Qiagen N.V. to Report First Half, 2024 Results on Aug 16, 2024

Qiagen N.V. Updates Earnings Guidance for the Full Year 2024

Qiagen N.V. to Report Q2, 2024 Results on Jul 31, 2024

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care

Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret

Qiagen Receives FDA Clearance for Qiastat-Dx Respiratory Syndromic Testing Panel for Fast and Accurate Results

Qiagen N.V., Annual General Meeting, Jun 21, 2024

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

QIAGEN Announces the Availability of QCI Secondary Analysis

Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations

QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use

Qiagen N.V. to Report Q1, 2024 Results on Apr 29, 2024

Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Full year 2023 earnings: EPS misses analyst expectations

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Full year 2023 earnings: EPS misses analyst expectations

Qiagen N.V. Provides Earnings Guidance for Year 2024

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Now 21% overvalued after recent price rise

Qiagen N.V. to Report Q4, 2023 Results on Feb 06, 2024

Qiagen N.V. Receives FDA Clearance of NeuMoDx CT/NG Assay for Use on Both Neumodx 96 and 288 Molecular Systems

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation

QIAGEN Launches New QIAcuity Digital PCR Kits and Updated Software to Expand Use by Biopharma and Food Safety Customers

Qiagen Launches Complete Sample to Insight Workflow for Microbiome Research

Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings: EPS misses analyst expectations

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen N.V. to Report Q3, 2023 Results on Oct 30, 2023

QIAGEN Launches QuantiFERON-EBV RUO Assay, Facilitating Research of Cell-Mediated Immune Response to Epstein-Barr Virus

QIAGEN Extends AI Capabilities of its NGS interpretation Software QCI Interpret to Enable Clinical Exome Completeness

QIAGEN Enhances QIAwave Portfolio with New Nucleic Acid Extraction Kits

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

CFO, MD & Member of Management Board recently sold US$1.3m worth of stock

CFO, MD & Member of Management Board notifies of intention to sell stock

Second quarter 2023 earnings: EPS misses analyst expectations

Qiagen N.V. Revises Earnings Guidance for the Full Year 2023

Now 20% undervalued

Qiagen N.V. to Report Q2, 2023 Results on Aug 08, 2023

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

QIAGEN’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-Analysis of Tuberculosis Screening

Qiagen N.V. Provides Earnings Guidance for the Year 2023

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook

Full year 2022 earnings: EPS misses analyst expectations

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Board Member recently sold US$218k worth of stock

Full year 2022 earnings: EPS misses analyst expectations